Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.
AYAs
Adolescents and young adults
Management
Multidisciplinary tumor board
NETSARC
Reference centers
Sarcoma
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Jan 2023
20 Jan 2023
Historique:
received:
21
05
2022
accepted:
17
01
2023
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level. NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15-30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors. Among 3,227 patients aged 15-30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3-83.6) in AYA in RSC and 82.7% (95%CI 79.4-85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively). This study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.
Sections du résumé
BACKGROUND
BACKGROUND
The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level.
PATIENTS AND METHODS
METHODS
NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15-30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors.
RESULTS
RESULTS
Among 3,227 patients aged 15-30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3-83.6) in AYA in RSC and 82.7% (95%CI 79.4-85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively).
CONCLUSIONS
CONCLUSIONS
This study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.
Identifiants
pubmed: 36670431
doi: 10.1186/s12885-023-10556-4
pii: 10.1186/s12885-023-10556-4
pmc: PMC9854049
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Informations de copyright
© 2023. The Author(s).
Références
Med Pediatr Oncol. 1995 May;24(5):279-80
pubmed: 7700177
Lancet Oncol. 2017 Mar;18(3):e166-e175
pubmed: 28271871
PLoS One. 2017 Feb 3;12(2):e0158406
pubmed: 28158190
Pediatr Blood Cancer. 2018 Sep;65(9):e27235
pubmed: 29770995
Pediatr Blood Cancer. 2019 Dec;66 Suppl 4:e27989
pubmed: 31568621
Cancer. 2020 Nov 1;126(21):4634-4659
pubmed: 32901932
Cancer Med. 2016 Jun;5(6):980-8
pubmed: 26929181
Pediatr Blood Cancer. 2018 Jul;65(7):e27013
pubmed: 29493075
J Bone Joint Surg Am. 1996 May;78(5):650-5
pubmed: 8642020
Curr Opin Oncol. 2017 Jul;29(4):268-274
pubmed: 28489620
Eur J Surg Oncol. 2006 Dec;32(10):1242-8
pubmed: 16793237
J Adolesc Young Adult Oncol. 2021 Feb;10(1):29-45
pubmed: 32412825
BMC Public Health. 2010 Apr 12;10:188
pubmed: 20384990
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267
pubmed: 30188977
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269
pubmed: 30285214
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95
pubmed: 30285218
PLoS One. 2011;6(8):e20294
pubmed: 21826194
Br J Cancer. 1994 Aug;70(2):352-62
pubmed: 8054285
Eur J Surg Oncol. 2020 Jul;46(7):1277-1286
pubmed: 31839437
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
Cancer. 2006 Apr 1;106(7):1425-30
pubmed: 16544312
Ann Oncol. 2017 Nov 01;28(11):2852-2859
pubmed: 29117335
Ann Surg. 2002 Mar;235(3):424-34
pubmed: 11882765
Clin Sarcoma Res. 2016 Nov 15;6:20
pubmed: 27891213
Eur J Surg Oncol. 2019 Jan;45(1):31-39
pubmed: 28985973
Eur J Oncol Nurs. 2007 Feb;11(1):74-81
pubmed: 16814605
Lancet. 1996 Aug 3;348(9023):313-8
pubmed: 8709693
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
Ann Transl Med. 2017 Feb;5(3):47
pubmed: 28251126
J Bone Joint Surg Br. 2008 Feb;90(2):203-8
pubmed: 18256089
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473